c-Oncogene Antibody Sampler Kit

• 产品编号：CST-9328S      品牌：Cell Signaling Technology       原厂货号：9328S
• 产品分类：抗体 > 一抗 > 复合抗体试剂盒
• 应用分类：

其它组分：

描述：

除非特殊说明，c-Oncogene Antibody Sampler Kit中的每个抗体都能检测内源性总靶蛋白水平，不能与相关蛋白发生交叉反应。c-Jun (60A8) Rabbit mAb能检测内源性总c-Jun蛋白水平，不管磷酸化位点如何。Ras (27H5) Rabbit mAb能检测内源性总K-Ras, H-Ras 和 N-Ras proteins蛋白水平。Src (36D10) Rabbit mAb能检测内源性Src蛋白水平，可能与其他Src家族成员发生交叉反应。该多克隆抗体通过使用与人源c-Rel蛋白周围残基、c-Raf蛋白脯氨酸（302位点）周围区域以蛋白羧端附近序列及c-Abl的合成肽段免疫动物而获得。该抗体经蛋白A和肽亲和层析纯化。该单克隆抗体通过使用与人源Src蛋白羧端周围残基、K-Ras蛋白胺端周围残基、c-Jun蛋白羧端附近序列、c-Fos蛋白序列、c-Myc 蛋白胺端周围序列以及c-Kit蛋白酪氨酸（703位点）周围残基相一致的合成肽段免疫动物而获得。c-Oncogene Antibody Sampler Kit为评估各种致癌蛋白水平提供了一个经济的方法。该试剂盒提供四次Western blot实验所需的足够的一抗和二抗。细胞生长、分化和程序性死亡的调节由一些蛋白设置协调，这些蛋白组成了重要的信号转导通路。其中许多关键的调节蛋白都是有前原癌基因编码，这些蛋白被活化后，原先典型的细胞程序改变，导致非正常的细胞生长以及发育紊乱。由原癌基因编码的蛋白包括生长因子和其他腺体、受体蛋白、酪氨酸激酶、各种调节蛋白（如GTP酶）和转录因子。这些蛋白共同组成了细胞信号转导通路的基本元件，一个或更多元件变化后的表达和突变会导致癌基因的生长（详见1中）。非受体（如胞质、胞核）酪氨酸激酶如c-Abl、Src对细胞增殖、分化、凋亡、细胞粘附和应激效应的调节起着关键作用(2,3)。相应的c-Abl、Src原癌基因的改变与癌基因的产生有关；Abl1-BCR基因的转位导致慢性粒细胞白细胞(CML)，而结构性活化Src蛋白出现于一些结肠癌患者体内，变化的Src蛋白表达出现于许多癌症疾病中(2,4)。Ras GTP酶对Ras酪氨酸激酶的调节控制了MEK/MAPK信号转导途径中的下游激酶(5)。Ras、Raf 原癌基因的活化在人类癌症中普遍存在，并且这两者都是临床治疗的潜在靶点(6)。受体酪氨酸激酶c-Kit在造血干细胞的生长和发育过程中起着重要的作用(7)；抑制c-Kit激酶活性的突变与各种发育紊乱相关，然而使c-Kit结构性活化的突变会导致肥大细胞增多症和胃肠道间质瘤(8)。c-Fos, c-Jun, c-Myc，c-Rel正常情况下会调节细胞、组织生长、分化和炎性/免疫反应，但是这些关键转录因子的改变也会导致不受控制的癌细胞生长(9-12)。

原厂资料：

Specificity / Sensitivity

Unless otherwise indicated, each antibody in the c-Oncogene Antibody Sampler Kit detects endogenous levels of total target protein and does not cross-react with related proteins. c-Jun (60A8) Rabbit mAb detects endogenous levels of total c-Jun protein, regardless of phosphorylation state. Ras (27H5) Rabbit mAb detects endogenous levels of total K-Ras, H-Ras and N-Ras proteins. Src (36D10) Rabbit mAb detects endogenous levels of Src proteins and may cross-react with other Src family members. The c-Myc (D84C12) Rabbit mAb detects endogenous levels of total c-Myc protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues near the carboxy terminus of human c-Rel, a region surrounding Pro302 of human c-Raf, and corresponding to the sequence close to the carboxy-terminus of human c-Abl. Antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibody is produced by immunizing animals with synthetic peptides corresponding to residues near the carboxy terminus of human Src, residues near the amino terminus of human K-Ras, from the amino-terminal sequence of human c-Jun, from the sequence of human c-Fos, residues near the amino terminus of c-Myc and corresponding to the residues surrounding Tyr703 of human c-Kit.

Description

The c-Oncogene Antibody Sampler Kit provides an economical means of evaluating total levels of various oncogenic proteins. The kit contains enough primary and secondary antibodies to perform four Western blot experiments.

Background

The regulation of cell growth, differentiation and programmed death is coordinated by several sets of proteins that comprise essential signal transduction pathways. Many of these key regulatory proteins are encoded by proto-oncogenes, which can be activated (altered) to change the typical cell program to one of abnormal cell growth and unregulated development. Proteins encoded by proto-oncogenes include growth factors and other ligands, receptor proteins, tyrosine kinases, various regulatory proteins (i.e. GTPases) and transcription factors. Together these proteins comprise the basic elements of cell signaling pathways; altered expression or mutation of one or more of these components can lead to oncogenic growth (reviewed in 1). 
 Non-receptor (i.e. cytoplasmic, nuclear) tyrosine kinases such as c-Abl and Src play key roles in the regulation of cell proliferation, differentiation, apoptosis, cell adhesion and stress responses (2,3). Alteration of the corresponding c-Abl and Src proto-oncogenes is associated with oncogenesis; Abl1-BCR gene translocations result in chronic myelogenous leukemia (CML) while constitutively active Src is seen in some patients with colon cancer and altered Src expression is seen in a wide array of cancers (2,4). Regulation of Raf tyrosine kinase by Ras GTPase controls downstream kinases in the MEK/MAPK signaling pathway (5). Activation of the Ras and Raf proto-oncogenes are common in human cancers and both proteins are seen as potential therapeutic targets (6). The receptor tyrosine kinase c-Kit plays a critical role in activation and growth of hematopoietic stem cells (7); mutations that inhibit c-Kit kinase activity are associated with a variety of developmental disorders while mutations producing constitutively active c-Kit can result in mastocytosis and gastrointestinal stromal tumors (8). The alteration of key transcription factors such as c-Fos, c-Jun, c-Myc and c-Rel that are normally responsible for regulating cell and tissue growth, differentiation and the inflammation/immune response, can also result in unregulated, oncogenic cell growth (9-12).

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol and less than 0.02%
sodium azide. Store at –20°C. Do not aliquot the antibodies